2-Hexadecanoylamino-2-methylpropane-1-ol | 36136-10-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-Hexadecanoylamino-2-methylpropane-1-ol
• 英文别名: N-(1-hydroxy-2-methylpropan-2-yl)hexadecanamide
• CAS: 36136-10-4
• 化学式: C₂₀H₄₁NO₂
• 分子量: 327.551
• InChiKey: WSEFKZYKIGSRKK-UHFFFAOYSA-N

物化性质

• 熔点：
  65-68 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
• 沸点：
  477.2±28.0 °C(Predicted)
• 密度：
  0.904±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  23
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Hexadecanoylamino-2-methylpropane-1-ol 200.0 ℃ 、2.0 kPa 条件下， 反应 6.0h， 生成 4,5-dihydro-4,4-dimethyl-2-pentadecyl-1,3-oxazole
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS FOR THE MODULATION OF SPECIFIC AMIDASES FOR N-ACYLETHANOLAMINES FOR USE IN THE THERAPY OF INFLAMMATORY DISEASES
  [FR] COMPOSITIONS ET PROCÉDÉS POUR LA MODULATION D'AMIDASES SPÉCIFIQUES POUR DES N-ACYLÉTHANOLAMINES EN VUE D'UNE UTILISATION DANS LA THÉRAPIE CONTRE LES MALADIES INFLAMMATOIRES

  摘要：

  公开号：

  WO2013121449A8
• 作为产物：
  描述：

  2-Hexadecanoylamino-2-methyl-propionic acid methyl ester 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.75h， 以82%的产率得到2-Hexadecanoylamino-2-methylpropane-1-ol
  参考文献：
  名称：

  A Synthesis of 2-Substituted 2-Aminoethanol Derivatives Having Inhibitory Activity against Protein Kinase C.

  摘要：

  合成了一系列2-氨基乙醇衍生物，并研究了它们对蛋白激酶C的抑制活性。在这些化合物中，2-内源性十六烷基氨基-5-诺尔戊烯-2-外源性甲醇（4h）和2-内源性十六烷基氨基-5-诺尔戊烯-2, 3-外源性二甲醇（4i）分别在2×10^-5 M和1×10^-5 M时抑制蛋白激酶C，但在1×10^-3 M浓度下对蛋白激酶A没有抑制作用。讨论了结构-活性关系。

  DOI：

  10.1248/cpb.40.122

文献信息

• COMPOSITIONS AND METHODS FOR THE MODULATION OF SPECIFIC AMIDASES FOR N-ACYLETHANOLAMINES FOR USE IN THE THERAPY OF INFLAMMATORY DISEASES
  申请人：Della Valle Francesco

  公开号：US20150057269A1

  公开（公告）日：2015-02-26

  The present invention regards compositions and methods for the modulation of amidases capable of hydrolysing N-acylethanolamines useable in the therapy of inflammatory diseases. In particular, the present invention regards a compound of general formula (I): enantiomers, diastereoisomers, racemes and mixtures, polymorphs, salts, solvates thereof, wherein: (a) R is a linear alkyl radical having 13 to 19 carbon atoms or alkenyl radical having 13 to 19 carbon atoms carrying a double bond; (b) X is 0 or S; (c) Y is a 2 or 3 carbon atom alkylene residue, optionally substituted with one or two groups equal or different from each other and selected from among the group consisting of: —CH 3 , —CH 2 OH, —COOCH 3 , —COOH. Y may preferably be: —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —, CH(CH 3 )—CH 2 —, —CH 2 —CH(CH 3 )—, —CH 2 —C(CH 3 ) 2 —, —CH 2 —CH(CH 2 OH)—, —CH 2 —C((CH 2 OH) 2 )—, —CH═CH—, —CH 2 —CH(COOCH 3 )—, —CH 2 —CH(COOH)—, for use as a medicine.

  本发明涉及用于调节能够水解N-酰乙醇胺的酰胺酶的组合物和方法，用于治疗炎症性疾病。具体来说，本发明涉及一般式(I)的化合物：对映体、非对映异构体、消旋体和混合物、多形态、盐、溶剂化合物，其中：(a) R是具有13至19个碳原子的直链烷基基团或具有13至19个碳原子并带有一个双键的烯基基团；(b) X为0或S；(c) Y为2或3个碳原子的烷基烃基残基，可选择地取代一个或两个相等或不同的基团，所述基团选自以下群组中的一种：—CH3、—CH2OH、—COOCH3、—COOH。Y可能更倾向于是：—CH2—CH2—、—CH2—CH2—CH2—、CH(CH3)—CH2—、—CH2—CH(CH3)—、—CH2—C(CH3)2—、—CH2—CH(CH2OH)—、—CH2—C((CH2OH)2—、—CH═CH—、—CH2—CH(COOCH3)—、—CH2—CH(COOH)—，用作药物。
• A synthesis of 2-endo-amino-2-exo-hydroxymethylnorbornenes having inhibitory activity against protein kinase C.
  作者：Tameo IWASAKI、Hiroyoshi YAMAZAKI、Takashi NISHITANI、Tadashi SATO

  DOI：10.1248/cpb.39.527

  日期：——

  2-endo-Hexadecylamino-2-exo-hydroxymethylnorbornene (1a) was synthesized from 2-acetamidonorbornene-2-carboxylic acid methyl ester (2) in a good overall yield. 2-endo-Hexadecylamino-2, 3-exo-bis(hydroxymethyl)norbornene (1b) was synthesized starting from dimethyl acetamidofumarate based on Diels-Alder strategy. 1a and 1b inhibited protein kinase C at the IC50 values of 2×10-5M and 1×10-5M, respectively, but not protein kinase A at a concentration of 1×10-3M. The structure-activity relationships are discussed.

  2-endo-Hexadecylamino-2-exo-hydroxymethylnorbornene (1a) 由 2-acetamidonorbornene-2-carboxylic acid methyl ester (2) 合成，总收率良好。2-endo-Hexadecylamino-2, 3-exo-bis(hydroxymethyl)norbornene (1b) 是基于 Diels-Alder 策略从乙酰氨基富马酸二甲酯开始合成的。1a 和 1b 对蛋白激酶 C 的抑制作用 IC50 值分别为 2×10-5M 和 1×10-5M，而对蛋白激酶 A 的抑制作用 IC50 值为 1×10-3M。本文讨论了结构-活性关系。
• Phospholipid analogs useful as paf synthesis inhibitors
  申请人：Merck & Co., Inc.

  公开号：EP0208961A2

  公开（公告）日：1987-01-21

  There are disclosed phospholipid analogs having the formula: wherein: Y represents, e.g., -O; R represents, e.g., -(CH2)15CH3; Z represents, e.g., X is, e.g., trimethylamine; R2 and R3 can be the same or different and are independently, e.g., (a) hydrogen; (b) hydroxy; (c) unsaturated or saturated, unsubstituted or substituted C1-C4 alkyl group wherein the substituents are hydroxy, acetyloxy, sulfhydryl, fluoro; (d) azido; (e) amido; (f) acetamido; m is, e.g., 1; and n is, e.g., 2. These compounds inhibit PAF (platelet-activating factor) biosynthesis and are thereby useful In the treatment of various diseases or disorders mediated by the PAF such as, for example, pain, fever, inflammation, cardiovascular disorder, asthma, lung edema, allergic disorders, skin diseases, psoriasis, and adult respiratory distress syndrome.

  已公开的磷脂类似物具有以下式子： 其中 Y 代表，例如，-O； R 代表，例如，-(CH2)15CH3； Z 代表，例如 X 代表三甲胺等； R2 和 R3 可以相同或不同，且各自独立，如 (a) 氢 (b) 羟基 (c) 不饱和或饱和、未取代或取代的 C1-C4 烷基，其中取代基为羟基、乙酰氧基、巯基、氟基； (d) 叠氮 (e) 氨基 (f) 乙酰氨基； m 是，例如 1；以及 n 是，例如 2。 这些化合物可抑制 PAF（血小板活化因子）的生物合成，因此可用于治疗由 PAF 介导的各种疾病或紊乱，例如疼痛、发热、炎症、心血管疾病、哮喘、肺水肿、过敏性疾病、皮肤病、牛皮癣和成人呼吸窘迫综合征。
• Modifications of the Ethanolamine Head in <i>N</i>-Palmitoylethanolamine:  Synthesis and Evaluation of New Agents Interfering with the Metabolism of Anandamide
  作者：Séverine Vandevoorde、Kent-Olov Jonsson、Christopher J. Fowler、Didier M. Lambert

  DOI：10.1021/jm0209679

  日期：2003.4.1

  The endogenous fatty acid amide anandamide (AEA) has, as a result of its actions on cannabinoid and vanilloid receptors, a number of important pharmacological properties including effects on nociception, memory processes, spasticity, and cell proliferation. Inhibition of the metabolism of AEA, catalyzed by fatty acid amide hydrolase (FAAH), potentiates the actions of AEA in vivo and therefore may be a useful target for drug development. In the present study, we have investigated whether substitution of the headgroup of the endogenous alternative FAAH substrate palmitoylethanolamide (PEA) can result in the identification of novel compounds preventing AEA metabolism. Thirty-seven derivatives of PEA were synthesized, with the C16 long chain of palmitic acid kept intact, and comprising 20 alkylated, 12 aromatic, and 4 halogenated amides. The ability of the PEA derivatives to inhibit FAAH-catalyzed hydrolysis of [H-3]AEA was investigated using rat brain homogenates as a source of FAAH. Inhibition curves were analyzed to determine the potency of the inhibitable fraction (pI(50) values) and the maximal attained inhibition for the compound, given that solubility in an aqueous environment is a major issue for these compounds. In the alkylamide family, palmitoylethyl-amide and palmitoylallylamide were inhibitors of AEA metabolism with PI50 values of 5.45 and 5.47, respectively. Halogenated derivatives (Cl and Br) exhibit PI50 values of similar to5.5 but rather low percentages of maximal inhibition. The -OH group of the ethyl head chain of N-palmitoylethanolamine was not necessary for interaction with FAAH. Amides containing aromatic moieties were less potent inhibitors of AEA metabolism. Compounds containing amide and ester bonds, 13 and 37, showed PI50 values of 4.99 and 5.08, respectively. None of the compounds showed obvious affinity for CB1 or CB2 receptors expressed on Chinese hamster ovary (CHO) cells. It is concluded that although none of the compounds were dramatically more potent than PEA itself at reducing the metabolism of AEA, the lack of effect of the compounds at CB1 and CB2 receptors makes them useful templates for development of possible therapeutic FAAH inhibitors.
• BEN-BASSAT, ALBERT A.;WASSERMAN, TAMAR, J. LIQUID CHROMATOGR., 10,(1987) N 13, 2939-2950
  作者：BEN-BASSAT, ALBERT A.、WASSERMAN, TAMAR

  DOI：——

  日期：——